NCT06293690View on ClinicalTrials.gov

Toripalimab Combined With SBRT for NSCLC

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 15, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2026

Conditions
Non-small Lung Cancer
Interventions
DRUG

Toripalimab

Patients received preoperative neoadjuvant therapy: SBRT 12gy on the first day, and Toripalimab (iv 240mg, q3W) combined with platinum-containing dual drugs on the second day. Two cycles in total.

DRUG

Toripalimab

Patients received preoperative neoadjuvant therapy: SBRT 12gy on the first day, and Toripalimab (iv 240mg, q3W) on the second day. Two cycles in total.

Trial Locations (1)

200000

Shanghai Pulmonary Hospital, Shanghai

All Listed Sponsors
lead

Shanghai Pulmonary Hospital, Shanghai, China

OTHER

NCT06293690 - Toripalimab Combined With SBRT for NSCLC | Biotech Hunter | Biotech Hunter